PharmaShots | Incisive News in 3 Shots

Subscribe Now

KRAS G12C

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer

Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II S...

October 8, 2021

Amgen Reports NDA Submission of Sotorasib to the US FDA for Advanced/Metastatic NSCLC With KRAS G12C Mutation

Amgen Reports NDA Submission of Sotorasib to the US FDA for Advanced/Metastatic NSCLC With KRAS G12C Mutation

December 17, 2020

Amgen's Sotorasib Receives the US FDA's Breakthrough Therapy Designation for Advanced or Metastatic NSCLC with KRAS G12C Mutation

Amgen's Sotorasib Receives the US FDA's Breakthrough Therapy Designation for Advanced or Metastatic NSCLC with KRAS G12C Mutation

December 9, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us